JUUL Labs Accuses NJOY and Altria of Patent Infringement; U.S. ITC Launches Section 337 Investigation

Sep.11.2025
JUUL Labs Accuses NJOY and Altria of Patent Infringement; U.S. ITC Launches Section 337 Investigation
The U.S. International Trade Commission (USITC) has instituted an investigation titled Certain Vaporizer Devices, Cartridges Used Therewith, and Components Thereof (II) based on a complaint by JUUL Labs, Inc. JUUL alleges that NJOY, its parent and affiliates at Altria Group, infringed U.S. Patent No. 12,156,533 through the importation and sale of certain ENDS devices, cartridges, and components. JUUL seeks a limited exclusion order and cease-and-desist orders. Respondents must answer within 20 d

Key Points

 

  • Investigation No.: 337-TA-1460; Institution Date: September 9, 2025.
  • Patent & Claims at Issue: U.S. Patent No. 12,156,533, claims 1–8 and 10.
  • Complainant: JUUL Labs, Inc. (Washington, D.C.).
  • Respondents: NJOY, LLC; NJOY Holdings, Inc.; Altria Group, Inc.; Altria Group Distribution Company; Altria Client Services LLC.
  • Accused Products (plain description): Electronic nicotine delivery systems (ENDS) / vaporizer devices, companion cartridges and parts (including cartridge housings, nicotine-salt e-liquids, heating elements/atomizers, chargers, batteries), and subcomponents.
  • Requested Relief: Limited Exclusion Order (LEO) and Cease-and-Desist Orders (C&D).
  • Procedure: A USITC Administrative Law Judge will conduct the hearing; the Office of Unfair Import Investigations (OUII) is not participating as a party.
  • Response Deadline: Respondents must file answers within 20 days of service. Failure to respond to each allegation may result in default and issuance of exclusion and/or cease-and-desist orders.

 


 

2Firsts, September 10, 2025 — The U.S. International Trade Commission (USITC) has issued a Notice of Institution initiating an investigation in Certain Vaporizer Devices, Cartridges Used Therewith, and Components Thereof (II) following a complaint filed by JUUL Labs, Inc. under Section 337 of the Tariff Act.

 

Complainant:

 

JUUL Labs, Inc.

 

 

Respondents:

 

NJOY, LLC

NJOY Holdings, Inc.

Altria Group, Inc.

Altria Group Distribution Company

Altria Client Services LLC

 

 

According to the notice, JUUL’s August 8, 2025 complaint alleges that respondents’ products, in the importation, sale for importation, or post-importation sale within the United States, infringe U.S. Patent No. 12,156,533 (the “‘533 patent”), specifically claims 1–8 and 10.

 

The USITC defines the scope of investigation in plain terms to include ENDS/vaporizer devices, their cartridges, and related components (such as cartridge housings, nicotine-salt e-liquids, heating elements/atomizers, chargers, batteries) as well as subcomponents.

 

JUUL requests that the Commission issue a limited exclusion order barring infringing products from entry into the United States and cease-and-desist orders against named domestic respondents.

 

The Commission’s Chief Administrative Law Judge will assign an ALJ to conduct proceedings. The USITC’s Office of Unfair Import Investigations (OUII) will not participate as a party in this matter.

 

Per the notice, respondents must file an answer within 20 days of service addressing each allegation in the complaint and the notice of investigation. Failure to do so may be deemed a waiver of the right to appear and contest, enabling the ALJ and Commission to make findings of fact and issue initial and final determinations that could result in exclusion and/or cease-and-desist orders.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05